|March 25, 2014|
|Verastem to Present Data on Product Candidates Targeting Cancer Stem Cells at the American Association of Cancer Research Meeting|
-New research to be presented in an oral session and three poster presentations-
“The four presentations at the upcoming AACR meeting demonstrate our
commitment to furthering the body of knowledge surrounding the role of
cancer stem cells as the driving factor in tumor progression,” said
The details of the presentations by
Title: VS-5584 a dual mTORC1/2 and PI3K inhibitor has anti-tumor
activity in multiple in vivo xenograft tumor models and enhanced
efficacy in combination with cisplatin or docetaxel
Title: Combined inhibition of PI3K isoforms and mTOR kinase is
critical for cancer stem cell inhibition by VS-5584
VS-6063 is an orally available compound designed to target cancer stem
cells through the potent inhibition of focal adhesion kinase (FAK).
Cancer stem cells are an underlying cause of tumor resistance to
chemotherapy, recurrence and ultimate disease progression. Research by
VS-5584 is an orally available compound that has demonstrated potent and
highly selective activity against class 1 PI3K enzymes and dual
inhibitory actions against mTORC1 and mTORC2 pathways. In preclinical
studies, VS-5584 has been shown to reduce the percentage of cancer stem
cells and induce tumor regression in taxane-resistant models.
Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.
|You may automatically receive Verastem Oncology™ financial information by e-mail. To choose your options for e-mail notification, please enter your e-mail address below and click Submit. On the next page you will be able to choose from the following options:|
To change your e-mail options at any time, re-enter your e-mail address and click Submit, then adjust your form entries.